Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy

Molecular Therapy

Volumn 22, Issue 6, 2014, Pages 1188-1197

  Cronin, Michelle ^a   Le Boeuf, Fabrice ^b   Murphy, Carola ^a   Roy, Dominic G ^b   Falls, Theresa ^b   Bell, John C ^b   Tangney, Mark ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; ONCOLYTIC VIRUS; TYPE 1 INTERFERON ANTAGONIST B18R; UNCLASSIFIED DRUG; VESICULAR STOMATITIS ONCOLYTIC VIRUS; B18R PROTEIN; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; REGULATOR PROTEIN; B18R PROTEIN, VACCINIA VIRUS; INTERFERON; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B18R GENE; BACTERIAL GENE; CANCER INHIBITION; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; SURVIVAL RATE; TUMOR RESISTANCE; VESICULAR STOMATITIS VIRUS INFECTION; VIRUS INFECTION; VIRUS REPLICATION; BACTERIAL GROWTH; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CANCER SURVIVAL; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; IMMUNE RESPONSE; LEWIS CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR VOLUME; VESICULAR STOMATITIS VIRUS; ADMINISTRATION AND DOSAGE; ANIMAL; CARCINOMA, LEWIS LUNG; GENE VECTOR; GENETICS; HT 29 CELL LINE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHARMACOLOGY; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE; VESICULOVIRUS; VIROLOGY;

BACTERIA (MICROORGANISMS); MUS; VESICULAR STOMATITIS VIRUS;

ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; ESCHERICHIA COLI; FEMALE; GENETIC VECTORS; HT29 CELLS; HUMANS; INJECTIONS, INTRAVENOUS; INTERFERON TYPE I; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VESICULOVIRUS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84902141909     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.23     Document Type: Article

References (35)

1. Le Boeuf, F, Diallo, JS, McCart, JA, Thorne, S, Falls, T, Stanford, M et al. (2010). Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 18: 888-895.
2. Russell, SJ, Peng, KW and Bell, JC (2012). Oncolytic virotherapy. Nat Biotechnol 30: 658-670.
3. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT, Knowles, S et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275. (Pubitemid 37329791)
4. Liu, TC, Hwang, T, Park, BH, Bell, J and Kirn, DH (2008). The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 16: 1637-1642.
5. Vähä-Koskela, MJ, Le Boeuf, F, Lemay, C, De Silva, N, Diallo, JS, Cox, J et al. (2013). Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma. J Virol 87: 2363-2366.
6. Le Boeuf, F, Batenchuk, C, Vähä-Koskela, M, Breton, S, Roy, D, Lemay, C et al. (2013). Model-based rational design of an oncolytic virus with improved therapeutic potential. Nat Commun 4: 1974.
7. Le Boeuf, F and Bell, JC (2010). United virus: the oncolytic tag-team against cancer! Cytokine Growth Factor Rev 21: 205-211.
8. Janelle, V, Poliquin, L and Lamarre, A (2013). [Vesicular stomatitis virus in the fight against cancer]. Med Sci (Paris) 29: 175-182.
9. Potts, KG, Hitt, MM and Moore, RB (2012). Oncolytic viruses in the treatment of bladder cancer. Adv Urol 2012: 404581.
10. Morrissey, D, O'Sullivan, GC and Tangney, M (2010). Tumour targeting with systemically administered bacteria. Curr Gene Ther 10: 3-14.
11. Baban, CK, Cronin, M, O'Hanlon, D, O'Sullivan, GC and Tangney, M (2010). Bacteria as vectors for gene therapy of cancer. Bioeng Bugs 1: 385-394.
12. Martins, FS, Silva, AA, Vieira, AT, Barbosa, FH, Arantes, RM, Teixeira, MM et al. (2009). Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Arch Microbiol 191: 623-630.
13. Schultz, M (2008). Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 14: 1012-1018.
14. Stritzker, J, Weibel, S, Hill, PJ, Oelschlaeger, TA, Goebel, W and Szalay, AA (2007). Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol 297: 151-162. (Pubitemid 46678925)
15. Cronin, M, Akin, AR, Collins, SA, Meganck, J, Kim, JB, Baban, CK et al. (2012). High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting. PLoS ONE 7: e30940.
16. Cronin, M, Stanton, RM, Francis, KP and Tangney, M (2012). Bacterial vectors for imaging and cancer gene therapy: a review. Cancer Gene Ther 19: 731-740.
17. Bell, J and Kirn, D (2010). Recent advances in the development of oncolytic viruses as cancer therapeutics. Foreword. Cytokine Growth Factor Rev 21: 83-84.
18. Tedcastle, A, Cawood, R, Di, Y, Fisher, KD and Seymour, LW (2012). Virotherapy- cancer targeted pharmacology. Drug Discov Today 17: 215-220.
19. Cronin, M, Morrissey, D, Rajendran, S, El Mashad, SM, van Sinderen, D, O'Sullivan, GC et al. (2010). Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. Mol Ther 18: 1397-1407.
20. Cummins, J and Tangney, M (2013). Bacteria and tumours: causative agents or opportunistic inhabitants? Infect Agents Cancer 8 11
21. Toso, JF, Gill, VJ, Hwu, P, Marincola, FM, Restifo, NP, Schwartzentruber, DJ et al. (2002). Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20: 142-152. (Pubitemid 34032605)
22. Nemunaitis, J, Cunningham, C, Senzer, N, Kuhn, J, Cramm, J, Litz, C et al. (2003). Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 10: 737-744. (Pubitemid 37243794)
23. Heppner, F and Möse, JR (1978). The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium. Acta Neurochir (Wien) 42: 123-125. (Pubitemid 8377876)
24. Bermudes, D, Low, B and Pawelek, J (2000). Tumor-targeted Salmonella. Highly selective delivery vectors. Adv Exp Med Biol 465: 57-63.
25. Karlsson, H, Larsson, P, Wold, AE and Rudin, A (2004). Pattern of cytokine responses to gram-positive and gram-negative commensal bacteria is profoundly changed when monocytes differentiate into dendritic cells. Infect Immun 72: 2671-2678. (Pubitemid 38542393)
26. Lehouritis, P, Springer, C and Tangney, M (2013). Bacterial-directed enzyme prodrug therapy. J Control Release 170: 120-131.
27. Ahmad, S, Casey, G, Cronin, M, Rajendran, S, Sweeney, P, Tangney, M et al. (2011). Induction of effective antitumor response after mucosal bacterial vector mediated DNA vaccination with endogenous prostate cancer specific antigen. J Urol 186: 687-693.
28. van Pijkeren, JP, Morrissey, D, Monk, IR, Cronin, M, Rajendran, S, O'Sullivan, GC et al. (2010). A novel Listeria monocytogenes-based DNA delivery system for cancer gene therapy. Hum Gene Ther 21: 405-416.
29. Tangney, M (2010). Gene therapy for cancer: dairy bacteria as delivery vectors. Discov Med 10: 195-200.
30. McGrath, S, Fitzgerald, GF and van Sinderen, D (2001). Improvement and optimization of two engineered phage resistance mechanisms in Lactococcus lactis. Appl Environ Microbiol 67: 608-616. (Pubitemid 32121348)
31. Riedel, CU, Monk, IR, Casey, PG, Morrissey, D, O'Sullivan, GC, Tangney, M et al. (2007). Improved luciferase tagging system for Listeria monocytogenes allows real-time monitoring in vivo and in vitro. Appl Environ Microbiol 73: 3091-3094. (Pubitemid 46718595)
32. Burns-Guydish, SM, Olomu, IN, Zhao, H, Wong, RJ, Stevenson, DK and Contag, CH (2005). Monitoring age-related susceptibility of young mice to oral Salmonella enterica serovar Typhimurium infection using an in vivo murine model. Pediatr Res 58: 153-158. (Pubitemid 40967447)
33. Brown, CW, Stephenson, KB, Hanson, S, Kucharczyk, M, Duncan, R, Bell, JC et al. (2009). The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol 83: 552-561.
34. Baban, CK, Cronin, M, Akin, AR, O'Brien, A, Gao, X, Tabirca, S et al. (2012). Bioluminescent bacterial imaging in vivo. J Vis Exp e4318.
35. Clancy, EK and Duncan, R (2009). Reovirus FAST protein transmembrane domains function in a modular, primary sequence-independent manner to mediate cell-cell membrane fusion. J Virol 83: 2941-2950.